Technical Analysis for MXCT - MaxCyte, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 4.64 | 18.07% | 0.71 |
MXCT closed up 18.07 percent on Wednesday, May 8, 2024, on 4.69 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 200 DMA | Bullish | 0.00% | |
| Crossed Above 50 DMA | Bullish | 0.00% | |
| Expansion Breakout | Bullish Swing Setup | 0.00% | |
| Expansion Pivot Buy Setup | Bullish Swing Setup | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Volume Surge | Other | 0.00% | |
| Wide Range Bar | Range Expansion | 0.00% | |
| Earnings Movers | Other | 0.00% | |
| Above Upper BB | Strength | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakout | about 17 hours ago |
| Rose Above Previous Day's High | about 17 hours ago |
| Rose Above Upper Bollinger Band | about 17 hours ago |
| Rose Above 200 DMA | about 17 hours ago |
| Rose Above 50 DMA | about 17 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/07/2024
MaxCyte is a leading provider of cell-engineering platform technologies to advance innovative cell-based research, development and potential commercialization of next-generation cell therapies. The company's existing customer base ranges from large biopharmaceutical companies — including 20 of the top 25 pharmaceutical companies based on 2020 global revenue — to hundreds of biotechnology companies and academic translational centers. MaxCyte has granted 13 strategic platform licenses to commercial cell therapy developers that allow for more than 75 clinical programs. Founded in 1998, MaxCyte is headquartered in Gaithersburg, Maryland, US.
Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Biotechnology Biopharmaceutical Life Sciences Pharmaceutical Pharmacy Cell Therapy Genscript Biotech Synbio
Classification
Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Biotechnology Biopharmaceutical Life Sciences Pharmaceutical Pharmacy Cell Therapy Genscript Biotech Synbio
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 5.545 |
| 52 Week Low | 2.45 |
| Average Volume | 602,104 |
| 200-Day Moving Average | 4.12 |
| 50-Day Moving Average | 4.11 |
| 20-Day Moving Average | 3.89 |
| 10-Day Moving Average | 3.86 |
| Average True Range | 0.25 |
| RSI (14) | 71.35 |
| ADX | 22.66 |
| +DI | 45.89 |
| -DI | 9.57 |
| Chandelier Exit (Long, 3 ATRs) | 4.38 |
| Chandelier Exit (Short, 3 ATRs) | 4.33 |
| Upper Bollinger Bands | 4.32 |
| Lower Bollinger Band | 3.46 |
| Percent B (%b) | 1.38 |
| BandWidth | 21.92 |
| MACD Line | -0.02 |
| MACD Signal Line | -0.11 |
| MACD Histogram | 0.0811 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 6.44 | ||||
| Resistance 3 (R3) | 6.41 | 5.77 | 6.14 | ||
| Resistance 2 (R2) | 5.77 | 5.31 | 5.79 | 6.04 | |
| Resistance 1 (R1) | 5.21 | 5.03 | 5.49 | 5.24 | 5.94 |
| Pivot Point | 4.57 | 4.57 | 4.72 | 4.59 | 4.57 |
| Support 1 (S1) | 4.01 | 4.11 | 4.29 | 4.04 | 3.34 |
| Support 2 (S2) | 3.37 | 3.83 | 3.39 | 3.24 | |
| Support 3 (S3) | 2.81 | 3.37 | 3.14 | ||
| Support 4 (S4) | 2.84 |
